Hesketh, P.J., Bohlke, K., Lyman, G.H., Basch, E., Chesney, M., Clark-Snow, R.A., . . . Kris, M.G. (2015). Antiemetics: American Society of Clinical Oncology focused guideline update. Journal of Clinical Oncology. Advance online publication.
PHASE OF CARE: Active antitumor treatment
Three studies were included in the review.
The oral combination of NEPA and dexamethasone is an option for patients receiving highly emetogenic chemotherapy (including anthracycline and cyclophosphamide) to meet recommendations for triple-drug therapy.
NEPA is a new drug that can be combined with NK1 and 5HT3 drugs. This drug provides both recommended agents in a single, oral medication. Patients who take NEPA rather than a typical regimen will not need IV administration, which can result in increased cost to the patient depending on individual insurance coverage.